China Vows to Defend Interests After U.S. Adds Genomics Firms to Blacklist
China's commerce ministry on Thursday condemned U.S. import restrictions on three Chinese genomics companies and vowed to take necessary measures to defend the country's interests.
The U.S. on Wednesday added BGI Genomics, MGI Tech and Shenzhen BGI Technology to its Uyghur Forced Labor Prevention Act Entity List, citing alleged links to forced labor in Xinjiang. The move requires importers to prove that goods from the companies weren't made with forced labor before they can enter the U.S. market.
China has repeatedly denied allegations of forced labor in Xinjiang. The commerce ministry said workers of all ethnic groups in the region enjoy freedom and equal employment opportunities, and that their labor rights are effectively protected by law.
The ministry accused Washington of using human rights as a pretext for unilateral protectionism and bullying, saying the latest restrictions came despite China's previous objections to U.S. sanctions targeting Chinese entities over Xinjiang. It said the measures violated the consensus reached by the two countries' leaders and seriously undermined the stability of bilateral economic and trade relations.
The ministry urged Washington to stop what it called political manipulation and attacks on Chinese companies.
Write to Singapore Editors at singaporeeditors@dowjones.com
(END) Dow Jones Newswires
October 29, 2026 02:43 ET (06:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
What 7 Key Market Indicators Are Telling Investors Right Now
United States